Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12321248 | 0.66 | NOS1 (0.56) | NOS1AXLCDK2CCNA1CCNA2 | |
| SCHEMBL20002212 | 0.64 | CDK2 (0.47) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL3004803 | 0.62 | NOS1 (0.40) | NOS1AXLCDK2CCNA1CCNA2 | |
| SCHEMBL29896270 | 0.62 | NOS1 (0.37) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL29896274 | 0.62 | NOS1 (0.37) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL2035935 | 0.62 | NOS1 (0.37) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL21219144 | 0.61 | ESR1 (0.41) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL19118540 | 0.60 | IDO1 (0.40) | TRPV1NOS1AXLCDK2CCNA1 | |
| SCHEMBL23178973 | 0.59 | CDK2 (0.42) | TRPV1NOS1AXLCDK2CCNA1 | |
| SCHEMBL4108777 | 0.59 | NOS1 (0.49) | TRPV1NOS1AXLCDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | claimed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | claimed |
| US-20100113565-A1 | IMMUNOSTIMULATORY COMBINATIONS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2010-05-06 | — | — | US | claimed |
| US-20100028381-A1 | FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-02-04 | — | — | US | claimed |
| US-20090246174-A1 | TREATMENT FOR CUTANEOUS T CELL LYMPHOMA | 3M INNOVATIVE PROPERTIES COMPANY | 2009-10-01 | — | — | US | claimed |
| EP-1804583-A4 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-05-20 | — | — | EP | claimed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | claimed |
| EP-1988896-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2008-11-12 | — | — | EP | claimed |
| EP-1968582-A2 | TREATMENT FOR CUTANEOUS T CELL LYMPHOMA | 3M Innovative Properties Company (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2008036312-A1 | FUNGICIDAL METHODS USING IMMUNE RESPONSE MODIFIER COMPOUNDS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| WO-2007079146-A1 | TREATMENT FOR NON-HODGKIN'S LYMPHOMA | COLEY PHARMACEUTICAL GROUP, INC (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1804583-A2 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1799256-A2 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST HIV | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006130399-A2 | THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006063152-A2 | IMMUNOSTIMULATORY COMBINATIONS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2006042254-A2 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2006026394-A2 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST HIV | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | GOVERNMENT OF THE UNITED STRATS OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2006-03-02 | — | — | US | claimed |
| US-20050267145-A1 | Treatment for lung cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2005-12-01 | — | — | US | claimed |
| US-20050226878-A1 | Therapeutic combinations and methods including IRM compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028381-A1 | FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS | GHITM, IFNG, ICOS | TRPV1 1323/4885NOS1 2324/4885AXL 4003/4885 |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TRPV1 4320/4885NOS1 3142/4885AXL 1437/4885 |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TRPV1 4320/4885NOS1 3142/4885AXL 1437/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | TRPV1 4320/4885NOS1 3142/4885AXL 1437/4885 |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | CD69, IRF3, CD4 | TRPV1 2423/4885NOS1 3183/4885AXL 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.